Advanced Ultrasound in Diagnosis and Therapy ›› 2026, Vol. 10 ›› Issue (3): 178-192.doi: 10.26599/AUDT.2026.250114
• ORIGINAL RESEARCH • Previous Articles Next Articles
Zhao Xiaohuia,b, Shen Xueqinc, Zhao Haiyued, Jin Dianshenga,b, Zhang Yua, Yang Dongfanga, Lan Xiuyana,b, Liu Yanga,b, Liu Xina, Li Shunana,*(
), Shi Xianquane,*(
)
Received:2025-12-05
Revised:2026-01-30
Accepted:2026-04-27
Online:2026-09-30
Published:2026-10-12
Contact:
Li Shunan, Shi Xianquan,
E-mail:522641997@qq.com;sonoshixq@ccmu.edu.cn
Zhao Xiaohui, Shen Xueqin, Zhao Haiyue, Jin Diansheng, Zhang Yu, Yang Dongfang, Lan Xiuyan, Liu Yang, Liu Xin, Li Shunan, Shi Xianquan. Ultrasound-targeted Microbubble Destruction Mediated miR-200a/PEG10 Axis Promotes Autophagy to Alleviate MAFLD. Advanced Ultrasound in Diagnosis and Therapy, 2026, 10(3): 178-192.
Table 1
Baseline characteristics of study participants"
| Parameter | Control group (n = 10) | MAFLD group (n = 10) | P-value |
| Age (years) | 65.1 ± 11.0 | 67.1 ± 8.7 | 0.658 |
| Sex (Male/Female) | 5/5 | 4/6 | 0.999 |
| BMI (kg/m2) | 23.4 ± 2.1 | 27.8 ± 3.2 | 0.002 |
| ALT (U/L) | 23.5 ± 6.8 | 72.3 ± 18.5 | < 0.0001 |
| AST (U/L) | 21.9 ± 5.2 | 54.6 ± 15.3 | < 0.0001 |
| TG (mmol/L) | 1.1 ± 0.3 | 2.6 ± 0.8 | < 0.0001 |
Table 2
Primer sequences"
| Gene | Primers sequences (5′-3′) |
| miR-200a | AATCCTGCTTGGGTATCAGG |
| GAGACCCAGTCTCAGGGAAA | |
| U6 | TGTCATCTCGCTCTGGTACG |
| AAATGACCCCTTCATCACCA | |
| PEG10 | ATTTGCTTTTGCCAAGAGTCAG |
| GGTGTGCCTTCATATTCAAACC | |
| Beclin1 | GAGGAGGACCGGATCAACG |
| CTGGAAGAGTGTTCGAGGCAG | |
| LC3 | TTGAAGGAGGATGTTCCCATCT |
| ACAGACACATATTTGGCATGGTT | |
| P62 | CAAGGCCCGTTTTCCACTAAG |
| GAGGCGATACAGGCCGATG | |
| PINK1 | CGAGAGCTACACGTTCACGG |
| GGGTGTCGAGGGAAAAATAGG | |
| Parkin | GACGCCATCAACACCGAGTT |
| CTTTGTCGTTGGTTAGCTGGT | |
| GAPDH | TGGATTTGGACGCATTGGTC |
| TTTGCACTGGTACGTGTTGAT |
Figure 2
PEG10 expression is increased in the MAFLD group, while miR-200a expression is decreased and negatively correlated with PEG10 mRNA levels. (A-B) Western blot detection of PEG10 protein expression; (C-D) Immunohistochemical detection of PEG10 expression; (E) qRT-PCR detection of miR-200a mRNA expression levels; (F) qRT-PCR detection of PEG10 mRNA expression levels; (G) Correlation analysis of miR-200a and PEG10 expression in liver tissues of MAFLD patients. *** denotes P < 0.001."
Figure 3
UTMD combined with the miR-200a/PEG10 signaling axis improves lipid metabolism, mitochondrial function, and inhibits apoptosis in MAFLD cells. (A) Oil Red O staining to detect lipid accumulation in each group; (B) qRT-PCR to detect miR-200a; (C) qRT-PCR to detect PEG10; (D) Electron microscopy to observe changes in mitochondrial morphology and structure within cells; (E) Dual-luciferase reporter assay to detect reporter gene expression levels; (F-G) Flow cytometry.* denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 0.001."
Figure 5
UTMD can deliver miR-200a mimics and siPEG10, ameliorate liver pathological damage in MAFLD mice, and reverse the autophagy inhibition state in MAFLD. (A) Liver tissue morphology; (B) Oil Red O staining of liver tissue; (C) Immunohistochemical staining to detect the expression of PEG10 in the liver; (D-E) PEG10 protein expression was analyzed by WB; (F-G) qPCR detection of miR-200a and PEG10 mRNA expression levels; (H-M) Beclin1, LC3B, P62, PINK1, and Parkin protein expression was analyzed by WB; (N-R) qRT-PCR analysis of the relative mRNA expression levels of Beclin1, PINK1, P62, LC3B, Parkin was analyzed by qRT-PCR. * denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 0.001."
Figure 6
3-MA or Rapa reverses or promotes the effects of UTMD combined with the miR-200a/PEG10 signaling axis on lipid metabolism, mitochondrial function, and apoptosis in MAFLD cells by influencing autophagy. (A-F) WB detection of the protein expression levels of Beclin1, LC3B, P62, PINK1, and Parkin in each group; (G-K) qPCR detection of the mRNA expression levels of Beclin1, LC3B, P62, PINK1, and Parkin in each group.* denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 0.001."
Figure 7
3-MA or Rapa reverses or promotes the effects of UTMD combined with the miR-200a/PEG10 signaling axis on MAFLD by influencing autophagy. (A-B) Apoptosis detected by flow cytometry; (C) qRT-PCR detection of PEG10; (D) qRT-PCR detection of miR-200a; (E) electron microscopy; (F) Oil Red O staining. * denotes P < 0.05, ** denotes P < 0.01, and *** denotes P < 0.001."
| [1] | Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Paris S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab 2023; 14: 20420188221145549. |
| [2] |
Bae SDW, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J (Engl) 2022; 135: 547-556.
doi: 10.1097/CM9.0000000000002089 |
| [3] |
Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021; 32: 500-514.
doi: 10.1016/j.tem.2021.04.008 |
| [4] |
Chen CL, Lin YC. Autophagy dysregulation in metabolic associated fatty liver disease: a new therapeutic target. Int J Mol Sci 2022; 23: 10055.
doi: 10.3390/ijms231710055 |
| [5] |
Zhu L, Wu X, Liao R. Mechanism and regulation of mitophagy in nonalcoholic fatty liver disease (NAFLD): a mini-review. Life Sci 2023; 312: 121162.
doi: 10.1016/j.lfs.2022.121162 |
| [6] |
Kouroumalis E, Voumvouraki A, Augoustaki A, Samonakis DN. Autophagy in liver diseases. World J Hepatol 2021; 13: 6-65.
doi: 10.4254/wjh.v13.i1.6 |
| [7] |
Nelson MC, O'Connell RM. MicroRNAs: at the interface of metabolic pathways and inflammatory responses by macrophages. Front Immunol 2020; 11: 1797.
doi: 10.3389/fimmu.2020.01797 |
| [8] |
Atic AI, Thiele M, Munk A, Dalgaard LT. Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2023; 324: C588-C602.
doi: 10.1152/ajpcell.00253.2022 |
| [9] |
Erceg S, Munjas J, Sopić M, Tomašević R, Mitrović M, Kotur-Stevuljević J, et al. Expression analysis of circulating miR-21, miR-34a and miR-122 and redox status markers in metabolic dysfunction-associated steatotic liver disease patients with and without type 2 diabetes. Int J Mol Sci 2025; 26: 2392.
doi: 10.3390/ijms26062392 |
| [10] |
Tobaruela-Resola AL, Milagro FI, Elorz M, Benito-Boillos A, Herrero JI, Mogna-Peláez P, et al. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for metabolic dysfunction-associated steatotic liver disease assessment. J Physiol Biochem 2025; 81: 1275-1288.
doi: 10.1007/s13105-024-01037-8 |
| [11] |
Magenta A, Ciarapica R, Capogrossi MC. The emerging role of miR-200 family in cardiovascular diseases. Circ Res 2017; 120: 1399-1402.
doi: 10.1161/CIRCRESAHA.116.310274 |
| [12] |
Alshahrani AF, Ashfaq F, Alsayegh AA, Bajahzer M, Khan MI, Beg MMA. MiRNA-200a and miRNA-200b expression, and vitamin-D level: prognostic significance in obese non-diabetic and obese type 2 diabetes mellitus individuals. World J Clin Cases 2024; 12: 6916.
doi: 10.12998/wjcc.v12.i36.6916 |
| [13] |
You P, Chen H, Han W, Deng J. miR-200a-3p overexpression alleviates diabetic cardiomyopathy injury in mice by regulating autophagy through the FOXO3/Mst1/Sirt3/AMPK axis. PeerJ 2023; 11: e15840.
doi: 10.7717/peerj.15840 |
| [14] |
Liang XL, Wang YL, Wang PR. MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm’s tumor via Wnt/β-catenin signaling pathway. Mol Cell Biochem 2021; 476: 2409-2420.
doi: 10.1007/s11010-021-04090-9 |
| [15] |
Torres JL, Novo-Veleiro I, Manzanedo L, Alvela-Suárez L, Macías R, Laso FJ, et al. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol 2018; 24: 4104-4118.
doi: 10.3748/wjg.v24.i36.4104 |
| [16] |
Kawai Y, Imada K, Akamatsu S, Zhang F, Seiler R, Hayashi T, et al. Paternally expressed gene 10 (PEG10) promotes growth, invasion, and survival of bladder cancer. Mol Cancer Ther 2020; 19: 2210-2220.
doi: 10.1158/1535-7163.MCT-19-1031 |
| [17] |
Zhang B, Liu Z, Wu R, Zhang CM, Cao K, Shan WG, et al. Transcriptional regulator CTR9 promotes hepatocellular carcinoma progression and metastasis via increasing PEG10 transcriptional activity. Acta Pharmacol Sin 2022; 43: 2109-2118.
doi: 10.1038/s41401-021-00812-3 |
| [18] |
Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, et al. Transcriptome changes in stages of non-alcoholic fatty liver disease. World J Hepatol 2022; 14: 1382-1397.
doi: 10.4254/wjh.v14.i7.1382 |
| [19] |
Wu J, Li RK. Ultrasound-targeted microbubble destruction in gene therapy: a new tool to cure human diseases. Genes Dis 2017; 4: 64-74.
doi: 10.1016/j.gendis.2016.08.001 |
| [20] |
Han Y, Sun J, Wei H, Hao J, Liu W, Wang X. Ultrasound-targeted microbubble destruction: modulation in the tumor microenvironment and application in tumor immunotherapy. Front Immunol 2022; 13: 937344.
doi: 10.3389/fimmu.2022.937344 |
| [21] |
Zhang H, Li Y, Rao F, Liufu C, Wang Y, Chen Z. A novel UTMD system facilitating nucleic acid delivery into MDA-MB-231 cells. Biosci Rep 2020; 40: BSR20192573.
doi: 10.1042/BSR20192573 |
| [22] |
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020; 40: 2082-2089.
doi: 10.1111/liv.14548 |
| [23] |
Zhou X, Liu H, Pang Y, Wang M, Liu S. UTMD-mediated delivery of miR-21-5p inhibitor suppresses the development of lung cancer. Tissue Cell 2022; 74: 101719.
doi: 10.1016/j.tice.2021.101719 |
| [24] |
Lo WY, Yang WK, Peng CT, Pai WY, Wang HJ. MicroRNA-200a/200b modulate high glucose-induced endothelial inflammation by targeting O-linked N-acetylglucosamine transferase expression. Front Physiol 2018; 9: 355.
doi: 10.3389/fphys.2018.00355 |
| [25] |
Feng G, He N, Gao J, Li XC, Zhang FN, Liu CC, et al. Causal relationship between key genes and MAFLD risk mediated by immune cells: a Mendelian randomization and mediation analysis. Diabetes Obes Metab 2024; 26: 5590-5599.
doi: 10.1111/dom.15925 |
| [26] | Zhu Y, Lin X. Identification of key genes for non-alcoholic steatohepatitis and gastric cancer by bioinformatics analysis. Hepatitis Monthly 2025;25. |
| [27] |
Rodriguez-Furlan C, Minina EA, Hicks GR. Remove, recycle, degrade: regulating plasma membrane protein accumulation. Plant Cell 2019; 31: 2833-2854.
doi: 10.1105/tpc.19.00433 |
| [28] |
Shi C, Xue W, Han B, Yang F, Yin Y, Hu C. Acetaminophen aggravates fat accumulation in NAFLD by inhibiting autophagy via the AMPK/mTOR pathway. Eur J Pharmacol 2019; 850: 15-22.
doi: 10.1016/j.ejphar.2019.02.005 |
| [29] | Onishi M, Yamano K, Sato M, Matsuda N, Okamoto K. Molecular mechanisms and physiological functions of mitophagy. EMBO J 2021; 40: e104705. |
| [30] |
Cao P, Wang Y, Zhang C, Sullivan MA, Chen W, Jing X, et al. Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy. J Nutr Biochem 2023; 120: 109414.
doi: 10.1016/j.jnutbio.2023.109414 |
| [31] |
Mao K, Jiang Q, Jiang Y, Fu Z, Hu J, Sun H, et al. Ultra-small micelles together with UTMD enhanced the therapeutic effect of docetaxel on glioblastoma. Eur J Pharm Sci 2023; 187: 106468.
doi: 10.1016/j.ejps.2023.106468 |
| [32] |
Li Y, Du M, Fang J, Zhou J, Chen Z. UTMD promoted local delivery of miR-34a-mimic for ovarian cancer therapy. Drug Deliv 2021; 28: 1616-1625.
doi: 10.1080/10717544.2021.1955041 |
| [33] |
Cao W, Li J, Yang K, Cao D. An overview of autophagy: mechanism, regulation and research progress. Bull Cancer 2021; 108: 304-322.
doi: 10.1016/j.bulcan.2020.11.004 |
| [34] |
Asmamaw Mengstie M. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges. Front Bioeng Biotechnol 2022; 10: 895713.
doi: 10.3389/fbioe.2022.895713 |
| [35] |
Wang Y, Shao W. Innate immune response to viral vectors in gene therapy. Viruses 2023; 15: 1801.
doi: 10.3390/v15091801 |
| [36] |
Cornelio OM, Teimurbaglou FR. Recent advances in nanoparticle-based targeted drug delivery systems: a comprehensive review. Nano Nexus & Applications 2026; 1: 12-23.
doi: 10.56975/ijsdr.v11i3.307742 |
| [37] | Zhao YX, Sun YY, Huang AL, Li XF, Huang C, Ma TT, et al. MicroRNA-200a induces apoptosis by targeting ZEB2 in alcoholic liver disease. Cell Cycle 2018; 17: 250-262. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
Share: WeChat
Copyright ©2018 Advanced Ultrasound in Diagnosis and Therapy
|
Advanced Ultrasound in Diagnosis and Therapy (AUDT) a>
is licensed under a Creative Commons Attribution 4.0 International License a>.
